News

A review of 57 real-world studies found that people with cystic fibrosis (CF) who take Kalydeco (ivacaftor) experience improvements in lung function, nutrition, and quality of life (QoL). Reduced healthcare system use, lower Pseudomonas…

Long-term use of Orkambi (lumacaftor/ivacaftor), an approved cystic fibrosis (CF) treatment, is safe and effective for children between ages 2 and 5 with two copies of the disease-causing F508del mutation in the CFTR gene, a study reported. It draws on results from a Phase 3 open-label extension trial…

When it comes to raising funds for cystic fibrosis (CF), the Cystic Fibrosis Foundation is committed to relentlessly pursuing research initiatives until “CF stands for cure found.” Last year, the foundation put a total of $218.1 million toward research and spent $80 million on its…

Cystic fibrosis (CF) is linked with changes in the types of cells — including stem cells — that compose the tissue lining the airways, a study reported. Specifically, CF patients show an exhaustion in certain basal cells, progenitor-like cells with the capacity to repair and regenerate damaged lung tissue.

Long before COVID-19 changed the world, organ transplant recipients were wearing masks to shield themselves from airborne threats. Immunosuppressive medicines, which often are a lifelong after a transplant, require these people to add an extra layer of protection against viruses as common as a cold or as dangerous as COVID. They…

Human mesenchymal stem cells (hMSCs) effectively treated infections caused by non-tuberculous mycobacteria in cell-based tests and a mouse model of cystic fibrosis (CF), a study revealed.  Although this strategy may help treat those infections in people with CF and other lung…

People living with cystic fibrosis (CF) are invited to participate in CF Awareness Month by submitting entries for the CF Awareness Film Festival, taking place virtually May 24–31. Supported by the Bonnell Foundation and the I See You Awards, the festival aims to highlight issues faced by…

Antibiotic-resistant infection with Mycobacterium abscessus bacteria in people with cystic fibrosis (CF) can evolve rapidly to become more virulent, a genetic analysis suggests.  The findings support early testing and treatment of lung infections before symptoms emerge to…

Eloxx Pharmaceuticals has announced that it’s now added the approved cystic fibrosis (CF) therapy Kalydeco (ivacaftor) to its global Phase 2 clinical program for ELX-02. Ongoing ELX-02 Phase 2 clinical trials, launched in 2019 with four treatment…

Note: This story was updated May 3, 2021, to specify that the Cystic Fibrosis Foundation’s Great strides events are all virtual this year.  Throughout May, Cystic Fibrosis (CF) Awareness Month, people will connect to share stories on social media, participate in fundraising events across the U.S.,…